electroCore (NASDAQ:ECOR – Get Free Report) and Biomerica (NASDAQ:BMRA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
Profitability
This table compares electroCore and Biomerica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| electroCore | -47.84% | -221.93% | -69.17% |
| Biomerica | -93.64% | -98.97% | -69.88% |
Volatility and Risk
electroCore has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| electroCore | $25.18 million | 1.64 | -$11.89 million | ($1.62) | -3.18 |
| Biomerica | $5.31 million | 1.56 | -$4.97 million | ($2.32) | -1.24 |
Biomerica has lower revenue, but higher earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings for electroCore and Biomerica, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| electroCore | 1 | 0 | 2 | 0 | 2.33 |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
electroCore currently has a consensus price target of $25.50, suggesting a potential upside of 395.15%. Given electroCore’s stronger consensus rating and higher possible upside, equities analysts clearly believe electroCore is more favorable than Biomerica.
Insider and Institutional Ownership
26.7% of electroCore shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 13.8% of electroCore shares are owned by company insiders. Comparatively, 15.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
electroCore beats Biomerica on 9 of the 13 factors compared between the two stocks.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
